Investor Alert: Robbins LLP Informs Stockholders of the Cerevel Therapeutics Holdings, Inc. Class Action

Core Viewpoint - A class action lawsuit has been filed against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC, and Pfizer, Inc. for allegedly misleading investors regarding a secondary stock offering and the subsequent merger with AbbVie Inc. [1][2] Group 1: Allegations and Impact - The lawsuit claims that Cerevel's secondary offering documents omitted crucial information about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which led to an artificially deflated stock price until the merger announcement [2] - Bain Capital, as Cerevel's controlling shareholder, allegedly purchased shares at this depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a profit exceeding$120 million when AbbVie announced the acquisition at $45 per share [2] - The action also seeks damages for investors who held shares as of January 8, 2024, due to misleading statements in Cerevel's January 18, 2024 Proxy statement regarding the nature and timing of AbbVie's interest [3] Group 2: Legal Proceedings - Shareholders interested in serving as lead plaintiffs must file their papers by June 3, 2025, to represent the class in the litigation [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Group 3: Firm Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5]